Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Other Collaborative and Royalty Revenue

Other Collaborative and Royalty Revenue % Chg.

Other Collaborative and Royalty Revenue Common Size

United States Product Revenue

United States Product Revenue % Chg.

United States Product Revenue Common Size

Outside of United States Product Revenue

Outside of United States Product Revenue % Chg.

Outside of United States Product Revenue Common Size

Other Revenue by Geography

Other Revenue by Geography % Chg.

Other Revenue by Geography Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

Trikafta / Kaftrio Revenue

Trikafta / Kaftrio Revenue % Chg.

Trikafta / Kaftrio Revenue Common Size

Symdeko / Symkevi Revenue

Symdeko / Symkevi Revenue % Chg.

Symdeko / Symkevi Revenue Common Size

Orkambi Revenue

Orkambi Revenue % Chg.

Orkambi Revenue Common Size

Kalydeco Revenue

Kalydeco Revenue % Chg.

Kalydeco Revenue Common Size

Casgevy Revenue

Casgevy Revenue % Chg.

Casgevy Revenue Common Size

Other Product Revenue

Other Product Revenue % Chg.

Other Product Revenue Common Size

Net Product Revenue

Net Product Revenue % Chg.

Net Product Revenue Common Size

Other Revenue

Other Revenue % Chg.

Other Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Alyftrek Revenue

Alyftrek Revenue Common Size

Journavx Revenue

Journavx Revenue Common Size

Revenue	LTM	Dec '24	Dec '23
Trikafta / Kaftrio Revenue	10,461	10,238.6	8,944.7
Symdeko / Symkevi Revenue	—	—	123
Orkambi Revenue	—	—	326
Kalydeco Revenue	—	—	475.5
Casgevy Revenue	69.5	10	—
Other Product Revenue	773.9	781.5	924.5
Net Product Revenue	11,692.6	11,020.1	9,869.2
Other Collaborative and Royalty Revenue	—	—	—
Other Revenue	30.7	—	—
Total Revenue	11,723.3	11,020.1	9,869.2

Revenue by Geography	LTM	Dec '24	Dec '23
Other Collaborative and Royalty Revenue	—	—	—
United States Product Revenue	7,294.5	6,684.9	6,040.4
Outside of United States Product Revenue	4,398.1	4,335.2	3,828.8
Other Revenue by Geography	30.7	—	—
Total Revenue by Geography	11,723.3	11,020.1	9,869.2